Advanced Enzyme Technologies Ltd (ADVENZYMES) AI Stock Analysis

• Market Cap: ₹30.49B
• Dividend Yield: 1.7%
• Average Volume (3M): 13.78K
• Price to Earnings (P/E): 19.9
• Beta (1Y): 1.09
• Revenue Growth: 14.11%
• EPS Growth: 7.47%
• Country: IN
• Employees: 323
• Sector: Healthcare
• Sector Strength: 45
• Industry: Chemicals - Specialty
• EPS (TTM): 2.80
• Shares Outstanding: 111,926,800
• 10 Day Avg. Volume: 10,375
• 30 Day Avg. Volume: 13,779
• PEG Ratio: -13.34
• Price to Book (P/B): 2.27
• Price to Sales (P/S): 5.07
• P/FCF Ratio: 28.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 14
• Revenue Forecast (FY): ₹7.51B

• Rating: 65 Neutral
• Price Target: ₹293.00 ▼(-3.38% Downside)
• Action: Reiterated Date: 10/07/25
• Date: Action: Reiterated 10/07/25

Advanced Enzyme Technologies Ltd scores well in financial performance due to its strong revenue and profit growth, solid margins, and effective leverage management. However, technical analysis indicates bearish momentum and valuation metrics suggest the stock is fairly priced but not a standout in terms of value. The absence of earnings call data and corporate events limits further insights.

Positive Factors

Consistent revenue & profit growth

Sustained revenue and profit growth reflects durable end-market demand for enzyme and probiotic consumables across human, animal and industrial uses. This recurring B2B revenue base supports predictable cash generation and funds R&D and geographic expansion over multi-quarter horizons.

High gross and net margins

Elevated gross (~48%) and net (>20%) margins indicate structural pricing power and efficient manufacturing/processing. High margins provide a persistent buffer versus input cost volatility, enabling reinvestment in product development and sustaining long-term profitability even during slower demand periods.

Very conservative balance sheet

Extremely low leverage and an 87.6% equity ratio give the company durable financial flexibility to fund capex, scale fermentation capacity, pursue strategic partnerships or withstand cyclical setbacks without relying on costly external debt, bolstering long-term resilience.

Negative Factors

Declining EBIT margin

A slipping EBIT margin signals rising operating costs or lower operational efficiency that, if persistent, can erode the company's strong net margins. Over several quarters this could constrain free cash flow available for reinvestment or reduce room to price competitively in key markets.

Modest free cash flow growth

Modest growth in free cash flow limits internal funding for capacity expansion, new product commercialisation and higher dividends. If growth ambitions accelerate, the company may need to raise financing or slow reinvestment, affecting strategic execution over the medium term.

ROE below industry leaders

A mid-single-digit ROE gap versus top peers implies returns to shareholders could lag unless management lifts asset efficiency or margins. Over time this could limit shareholder upside relative to competitors unless productivity or growth materially improves.

Advanced Enzyme Technologies Ltd Business Overview & Revenue Model

Company Description

Advanced Enzyme Technologies Limited researches and develops, manufactures, and markets enzymes and probiotics in India, the United States, Asia, Europe, and internationally. The company offers enzymes for human healthcare and animal nutrition, fruit and vegetable processing, baking, brewing, and malting, and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as for specialty applications. It also provides non-food processing enzymes for textile processing, leather, pulp and paper, detergents and cleaning aids, bio-fuels, and biocatalysis. The company was formerly known as Advanced Biochemicals Limited and changed its name to Advanced Enzyme Technologies Limited in 2005. Advanced Enzyme Technologies Limited was founded in 1957 and is based in Thane, India.

How the Company Makes Money

ADVENZYMES primarily makes money by selling enzyme- and probiotic-based products to business customers (B2B) and, where applicable, through branded or finished formulations sold via channel partners. Its revenue model is centered on (1) product sales across distinct application segments—such as human nutrition/health (e.g., nutraceutical and dietary supplement ingredients), animal nutrition (e.g., feed enzymes and probiotics), food processing (e.g., enzymes used to improve yields, clarity, texture, or processing efficiency), and other industrial uses (enzyme solutions tailored to specific industrial processes); and (2) recurring demand driven by customers’ ongoing production needs, since enzymes are typically consumable inputs used continuously in manufacturing or processing. Earnings are influenced by the company’s ability to develop differentiated strains/formulations, scale fermentation and downstream processing efficiently, maintain quality and regulatory compliance for targeted end-uses, and expand distribution in export markets. Specific details on the breakdown of revenue by segment, pricing structure, named partnerships, or customer concentration are null.

Advanced Enzyme Technologies Ltd Financial Statement Overview

Summary

Advanced Enzyme Technologies Ltd demonstrates a strong financial position with consistent revenue and profit growth, solid profit margins, and effective leverage management. While the slight decline in EBIT margin and modest free cash flow growth present areas for improvement, the company remains financially sound with minimal risk.

Income Statement

Advanced Enzyme Technologies Ltd shows a strong income statement with consistent revenue growth, evidenced by a 6.8% increase in the latest year. The company maintains high profit margins, with a net profit margin of over 20% and a gross profit margin around 48%. However, the slight decline in EBIT margin suggests efficiency improvements are needed. Overall, the company is financially healthy with robust profitability.

Balance Sheet

The balance sheet indicates a solid financial structure with a low debt-to-equity ratio of 0.03, showcasing strong leverage management. The equity ratio stands at a stable 87.6%, indicating reliance on equity financing. The return on equity is healthy at 9.2%, though slightly lower than industry leaders. Overall, the company displays a stable and conservative balance sheet with minimal financial risk.

Cash Flow

The cash flow statement reflects robust operating cash flows with a steady growth trend. The free cash flow to net income ratio is favorable, indicating efficient cash generation relative to earnings. However, the free cash flow growth rate has been modest. The company manages its capital expenditures prudently, but could enhance free cash flow growth further.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	7.07B	6.37B	6.23B	5.41B	5.29B	5.00B
Gross Profit	4.80B	3.07B	4.64B	3.98B	4.09B	3.95B
EBITDA	2.53B	2.27B	2.27B	1.79B	2.09B	2.41B
Net Income	1.47B	1.31B	1.33B	1.06B	1.20B	1.46B
Balance Sheet
Total Assets	16.92B	16.21B	15.35B	14.22B	12.68B	11.53B
Cash, Cash Equivalents and Short-Term Investments	6.19B	5.88B	5.48B	4.86B	3.74B	3.17B
Total Debt	346.54M	393.50M	473.08M	334.99M	347.30M	279.63M
Total Liabilities	1.58B	1.53B	1.64B	1.38B	1.27B	1.22B
Stockholders Equity	14.85B	14.21B	13.24B	12.35B	10.89B	9.71B
Cash Flow
Free Cash Flow	463.75M	1.15B	990.56M	1.02B	941.15M	1.43B
Operating Cash Flow	647.13M	1.49B	1.41B	1.40B	1.22B	1.63B
Investing Cash Flow	-307.26M	-990.44M	-646.49M	-2.98B	-249.12M	-260.33M
Financing Cash Flow	-652.83M	-692.02M	-592.38M	-257.98M	-273.75M	-263.10M

Advanced Enzyme Technologies Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 303.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ADVENZYMES, the sentiment is Negative. The current price of 303.25 is above the 20-day moving average (MA) of 292.09, above the 50-day MA of 290.54, and below the 200-day MA of 312.99, indicating a bearish trend. The MACD of -5.61 indicates Positive momentum. The RSI at 37.73 is Neutral, neither overbought nor oversold. The STOCH value of 18.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ADVENZYMES.

Advanced Enzyme Technologies Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPGLIFE	76 Outperform	₹31.08B	43.39	―	0.85%	―	―
ADVENZYMES	65 Neutral	₹30.49B	19.90	―	1.70%	14.11%	7.47%
DCAL	58 Neutral	₹24.87B	-74.58	―	―	5.38%	―
GUFICBIO	57 Neutral	₹29.54B	67.80	―	0.03%	7.78%	-34.68%
MOREPENLAB	57 Neutral	₹20.28B	20.54	―	0.49%	-0.29%	-29.04%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%